相似文献
1
Expected Response to the Additional Fifth Dose of COVID-19 Vaccine.
Int J Prev Med. 2023 Sep 28;14:112. doi: 10.4103/ijpvm.ijpvm_146_22. eCollection 2023.
2
Humoral antibody response following mRNA vaccines against SARS-CoV-2 in solid organ transplant recipients; a status after a fifth and bivalent vaccine dose.
Front Immunol. 2023 Nov 27;14:1270814. doi: 10.3389/fimmu.2023.1270814. eCollection 2023.
3
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season.
MMWR Recomm Rep. 2021 Aug 27;70(5):1-28. doi: 10.15585/mmwr.rr7005a1.
4
Expected response to the additional third dose of COVID-19 vaccine based on different complete standard vaccination background.
Int J Physiol Pathophysiol Pharmacol. 2022 Feb 15;14(1):1-3. eCollection 2022.
5
Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccine.
Vaccine. 2003 Jun 2;21(19-20):2298-306. doi: 10.1016/s0264-410x(03)00173-7.
6
Relative vaccine effectiveness of ChAdOx1/AZD1222 vaccines as booster dose via intradermal injection with a one-fifth dose compared with the intramuscular injection in the prevention of SAR-CoV-2 infections in Phuket: A retrospective cohort study.
Int J Infect Dis. 2024 Oct;147:107179. doi: 10.1016/j.ijid.2024.107179. Epub 2024 Jul 31.
7
Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children.
Pediatrics. 2000 Jan;105(1):e11. doi: 10.1542/peds.105.1.e11.
8
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
9
Relative vaccine effectiveness of mRNA COVID-19 boosters in people aged at least 75 years during the spring-summer (monovalent vaccine) and autumn-winter (bivalent vaccine) booster campaigns: a prospective test negative case-control study, United Kingdom, 2022.
Euro Surveill. 2023 Nov;28(48). doi: 10.2807/1560-7917.ES.2023.28.48.2300173.
10
Analysis of mRNA COVID-19 Vaccine Uptake Among Immunocompromised Individuals in a Large US Health System.
JAMA Netw Open. 2023 Jan 3;6(1):e2251833. doi: 10.1001/jamanetworkopen.2022.51833.
引用本文的文献
1
Antibody Response After a Fifth Dose (Third Booster) of BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers.
J Clin Med. 2024 Oct 31;13(21):6538. doi: 10.3390/jcm13216538.
本文引用的文献
1
The DiaCoVAb Study in South Italy: Immune Response to SARS-CoV-2 Vaccination in Dialysis Patients.
Kidney Blood Press Res. 2022;47(7):467-474. doi: 10.1159/000524034. Epub 2022 Mar 22.
2
Expected response to the additional third dose of COVID-19 vaccine based on different complete standard vaccination background.
Int J Physiol Pathophysiol Pharmacol. 2022 Feb 15;14(1):1-3. eCollection 2022.
3
Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron.
N Engl J Med. 2022 Apr 7;386(14):1377-1380. doi: 10.1056/NEJMc2202542. Epub 2022 Mar 16.
4
Improved Antibody Response After a Fifth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series.
Transplantation. 2022 May 1;106(5):e262-e263. doi: 10.1097/TP.0000000000004092. Epub 2022 Feb 15.
5
Fourth COVID-19 Vaccine Dose Increases Low Antibodies.
JAMA. 2022 Feb 8;327(6):517. doi: 10.1001/jama.2022.0727.
6
Fourth dose of COVID-19 vaccines in Israel.
Lancet Respir Med. 2022 Feb;10(2):e19. doi: 10.1016/S2213-2600(22)00010-8. Epub 2022 Jan 11.
7
Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series.
Ann Intern Med. 2022 Mar;175(3):455-456. doi: 10.7326/L21-0598. Epub 2022 Jan 11.
8
COVID-19 Vaccine Booster: To Boost or Not to Boost.
Infect Dis Rep. 2021 Oct 28;13(4):924-929. doi: 10.3390/idr13040084.
9
Assessment of 4 Doses of SARS-CoV-2 Messenger RNA-Based Vaccine in Recipients of a Solid Organ Transplant.
JAMA Netw Open. 2021 Nov 1;4(11):e2136030. doi: 10.1001/jamanetworkopen.2021.36030.
10
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.
Lancet. 2021 Dec 4;398(10316):2093-2100. doi: 10.1016/S0140-6736(21)02249-2. Epub 2021 Oct 29.
Zotero 插件